Review Article

The Complementary and Alternative Medicine for Polycystic Ovary Syndrome: A Review of Clinical Application and Mechanism

Li-Yan Jia, Jia-Xing Feng, Juan-Li Li, Fang-Yuan Liu, Liang-zhen Xie, Shou-Juan Luo, and Feng-Juan Han

1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China
2Heilongjiang University of Chinese Medicine, Harbin, China
3Digestive Hospital of Heilongjiang Hospital, Harbin, China

Correspondence should be addressed to Shou-Juan Luo; luoshoujuan1978@163.com and Feng-Juan Han; hanfengjuan2004@163.com

Received 6 January 2021; Revised 8 February 2021; Accepted 19 February 2021; Published 26 February 2021

1. Introduction

Polycystic ovary syndrome (PCOS) is a reproductive endocrine disease characterized by menstrual disorder, infertility, and obesity, usually accompanied by insulin resistance and metabolic disorders [1]. Due to various reasons such as bad eating habits and unprecedented psychological and social pressure, its incidence has gradually increased as high as 5%–10% [2, 3]. The pathogenesis of PCOS is relatively complex, which may be closely related to genetic factors, endocrine, and specific environment [4]. It is usually diagnosed with the Rotterdam diagnostic criteria. According to the pathophysiology and clinical characteristics of PCOS, the treatment of PCOS includes exercise to lose weight, decrease androgen, and improve insulin resistance (IR), oral contraceptives to regulate the menstrual cycle, and ovulation induction. These conventional treatments, however, have problems such as adverse reactions, low compliance, poor efficacy, and even contraindications [5]. Therefore, it is urgent to find a more effective treatment for PCOS.

Complementary and alternative medicine (CAM), an alternative therapy independent of Western medicine, has been extensively used in health care systems around the world. Numerous studies have indicated that using CAM including acupuncture, Chinese herbal medicine, Tai Chi, yoga, and Qigong can also effectively treat PCOS with fewer adverse reactions. Based on this, the purpose of this review is to provide more accurate evidence for the treatment of PCOS by CAM and to analyze its underlying mechanisms.

2. Acupuncture

Acupuncture, an indispensable part of CAM, has been used in China for more than 3000 years. With the modernization of TCM, more and more Western countries have begun to
apply it for treating and preventing diseases. Due to its superiorities, namely, ease of operation, economical and satisfactory effect, etc., acupuncture has gradually been used in the treatment of PCOS. According to literature searched at the database PubMed and CNKI, we concluded that after thousands of years of development, acupuncture has not only been limited to its original model but has gradually evolved into different forms such as acupuncture, electro-acupuncture, warm acupuncture, acupoint embedding, and auricular points [6, 7]. At present, there are different mechanisms of acupuncture for PCOS summarized through considerable clinical and animal trials such as the fact that it can regulate the function of the hypothalamus-pituitary-ovarian axis (HPOA) and the metabolism, promote ovulation, and improve insulin resistance (IR) and endometrial receptivity (ER) [8, 9].

2.1. Acupuncture. Acupuncture refers to using the needle inserted into the patient’s specific area of the body at a certain angle to cure diseases through the manipulations such as twisting, lifting, and thrusting [10]. Several studies have proven that acupuncture is beneficial in treating PCOS. A review summarized from limited evidence-based studies showed that acupuncture can be effective in improving PCOS-related symptoms, including the induction of ovulation and restoration of menstruation [11]. An animal experiment conducted by Zhang showed that acupuncture could significantly reduce the number of cystic expanded follicles and the rate of cystic expanded follicles, increase the corpus luteum, and significantly improve the ovarian morphology [12]. In addition, other studies have shown that acupuncture can reduce the incidence of PCOS by changing the distribution of specific intestinal flora, increasing the content of beneficial bacteria, and maintaining the balance between the internal and external environment of the patients [13]. Ee designed a protocol to verify their hypothesis that the mechanism of acupuncture for obese PCOS patients is improving IR [14].

Wu et al. [15] randomized 112 obese PCOS patients into the treatment group and control group. The treatment group was administrated with metformin combined with acupuncture Xiawan (CV10), Zhongwan (CV12), Guanyuan (CV4), Qihai (CV6), Tianshu (ST25), Shuidao (ST28), and bilateral Liangmen (ST21), while the control group was merely given metformin. After 3 months, they found that, in obese PCOS patients, acupuncture can effectively improve the ovarian function by regulating the luteinizing hormone (LH), the follicle-stimulating hormone (FSH), and the testosterone (T) and reducing LH/FSH, leptin (LEP), and obesity. Its mechanism may be related to the reduction of LEP [16]. Jin et al. [17] summarized 52 articles on the rules of acupuncture in PCOS patients and concluded that the most frequently used acupoints were Sanyinjiao (SP6), CV4, Zigong (EX-CA), Zhongji (CV3), and CV6. Ren [18] conducted a systematic review and meta-analysis on the treatment of PCOS with acupuncture and concluded that acupuncture can reduce HOMA-IR and BMI, promote ovulation, increase pregnancy rate, etc. while ensuring the safety of the treatment. However, due to issues such as the quality of the literature, further researches are needed to prove its effectiveness. Based on the data analysis, Yu et al. [19] outlined the rules of acupoint-selection for PCOS (Table 1).

2.2. Electroacupuncture (EA). With the increasing application of acupuncture in Western countries, EA, a derivative of acupuncture, is gradually being used in the treatment of PCOS. EA refers to the combination of electric current with acupuncture to achieve the purpose of strengthening the stimulus [20]. At present, the mechanism of EA on PCOS has not been clarified. Xu G conducted an animal experiment showing that the number of immature follicles, the FSH, the LH/FSH, and the serum anti-Müllerian hormone (AMH) were decreased by EA stimulated on CV4, SP6, and ST36 [21]. Similarly, some studies have shown that EA can correct the imbalance of FSH and AMH in PCOS granulosa cells by inhibiting the excessive secretion of AMH, thus improving hyperandrogenemia and follicular development stagnation [22]. Peng et al. concluded that EA can improve IR, mitochondrial dysfunction, and ER by enhancing autophagy in PCOS-like rats [23].

Budihastuti UR randomized 44 PCOS patients into a control group and an EA group. The EA group was treated for 15 minutes per time, twice a week, for six consecutive weeks. The results show that EA can promote the growth of oocytes in PCOS patients [24]. Li [25] conducted a study on 62 PCOS patients undergoing IVF-ET and found that EA can improve the quality of oocytes. The mechanism may be as follows: EA acts on HPOA to regulate the secretion of gonadotropin-releasing hormone or increase the sensitivity of the pituitary to gonadotropin, indirectly regulate the secretion of FSH, and then improve the quality of follicles and embryos. Cui [26] also reached the same conclusion in the RCT and proposed that its mechanism may be related to the changes of the ovarian microenvironment.

2.3. Acupoint Catgut Embedding. Acupoint catgut embedding refers to using needles and absorbable catgut to stimulate meridians, balance yin, and yang, reconcile qi, and blood to achieve the purpose of curing diseases [27]. Acupoint catgut embedding not only has a function similar to acupuncture but can also stimulate continuous and spontaneous. The superiority of it lies in its remarkable and stable efficacy in treating disease with fewer adverse reactions. Numerous researches have confirmed the effectiveness and have elaborated the mechanism of acupoint catgut embedding in PCOS. Lin [28] conducted an animal experiment to explore the mechanism of acupoint catgut embedding in PCOS. They found that acupoint catgut embedding can significantly improve IR and increase the expression of MiR-125b in PCOS rats’ ovaries. MiR-125b can reduce the high expression of ERK1 and ERK2, downregulate the abnormal activation of the MAPK/ERK pathway, restore the balance between proliferation and apoptosis of granulosa cells, and reduce the excessive synthesis of androgen by theca cells. It may be the epigenetic posttranscriptional mechanism of
increase SOD activity, reduce MDA level, and improve acupuncture can effectively reduce T, LH, and LH/FSH, according to BMI. Both groups were treated with warming acupuncture for 3 cycles. The results show that warming acupuncture can effectively reduce T, LH, and LH/FSH, ovulation rate, and mechanism of TCM monomer and TCM compound in PCOS [37]. Because of its time-saving and low-cost characteristics, it is inexpensive, so it has a high acceptance rate and is worthy of further promotion in clinical practice. Yu et al. [30] analyzed the published literature and concluded that the top 10 acupoints used in acupoint catgut embedding for PCOS were ST25, CV4, ST40, SP6, GB26, BL23, CV12, ST36, CV6, and SP9. Due to the heterogeneity of the small sample size and low quality of literature, more clinical trials are needed to verify its efficacy to promote the clinical application.

### 2.4. Other Acupuncture Therapies

#### 2.4.1. Warming Acupuncture

Warming acupuncture refers to the process of keeping the needle, twisting the moxa mass around the needle handle to ignite, and transferring heat into the acupoints through the needle. Warming acupuncture is also a combination of acupuncture and moxibustion. Lin et al. [31] randomized 58 PCOS patients into a control group (using acupuncture treatment) and a treatment group (using warming acupuncture). After 3 sessions of treatment, the effective rates of the two groups were 66.67% and 44.43%, respectively. Xu’s clinical trials also reached the same conclusion that warming acupuncture can treat PCOS effectively. The results showed that after treatment, the observation group was better than the control group in terms of ovarian volume, follicle number, ovulation number, pregnancy rate, etc. (P < 0.05) [32]. Gu [33] divided 62 PCOS patients into the obese group and nonobese group according to BMI. Both groups were treated with warming acupuncture for 3 cycles. The results show that warming acupuncture can effectively reduce T, LH, and LH/FSH, increase SOD activity, reduce MDA level, and improve oxidative stress (OS) in PCOS patients. Through comparison, we found that warming acupuncture improves the OS level of obese PCOS patients more significantly than non-obese PCOS patients.

#### 2.4.2. Auricular Points

When problems occur in certain parts of the body, it will react in the corresponding of the auricle. These parts refer to the auricular point. Auricular point is mainly used to treat various diseases by stimulating auricular point, which has been used as adjuvant therapy for a long time in China. The main methods of stimulating auricular point are acupuncture, embedding needle, bloodletting, auricular point sticking, magnetic therapy, massage, etc. [34]. Gao [35] randomized 60 patients with PCOS infertility into a treatment group (30 participants) and a control group (30 participants). The treatment group was given auricular points, and the control group was given oral Chinese herb medicine (CHM). The total effective rate of these two groups was 53.3% and 46.7%, respectively. There was no difference between the two groups. It shows that auricular points for PCOS infertility have an equal effect of CHM. Studies have also reported that the mechanism of auricular points in PCOS is that it can regulate the functions of the anterior pituitary and ovaries [36]. Compared with other CAMs, the auricular point is easy to operate and inexpensive, so it has a high acceptance rate and is worthy of promotion.

### 3. Chinese Herbal Medicine

As a part of CAM, CHM has saved thousands of Chinese people in the development of China. It started with Shen Nong, a medical scientist in ancient China. After thousands of years’ exploration and practice, CHM has gradually become a major part of China’s medical system. The clinical efficacy of CHM is remarkable, especially for gynecological diseases such as dysmenorrhea, infertility, and PCOS [37]. The following content mainly focuses on the clinical efficacy and mechanism of TCM monomer and TCM compound in PCOS [38, 39].

| Meridian          | Acupoints                                                                 |
|-------------------|---------------------------------------------------------------------------|
| Ren meridian      | Guan yuan (CV4), zhong ji (CV3), qi hai (CV6), zhong wan (CV12), shui feng (CV9), qu gu (CV2), dan zhong (CV17) |
| Spleen meridian of foot-Taiyin | San yin jiao (SP6), xue hai (SP10), yin ling quan (SP9), da heng (SP15), di ji (SP8) |
| Stomach meridian of foot-Yangming | zu san li (ST36), tian shu (ST25), gui lai (ST29), feng long (ST40), hua rou men (ST24), shui dao (ST28) |
| Bladder meridian of foot-Taiyang | Shen shu (BL23), pi shu (BL20), gan shu (BL18), ge shu (BL17), ci liao (BL32) |
| Extra points      | Zi gong (EX-CA1), luan chao (TF2) |
| Kidney meridian of foot-Shaoxin | Tai xi (KI3), da he (KI12), heng gu (KI11), fu liu (KI7) |
| Liver meridian of foot-Jueyin | Tai chong (LR3), xing jian (LR2) |
| Du meridian       | Bai hui (GV20), ming men (GV4), da zhui (GV14) |
| Large intestine meridian of hand-Taiyang | he gu (LI4) |
| Pericardium meridian of hand-Jueyin | Nei guan (PC6) |
| Gallbladder meridian of foot-Shaoyang | Dai mai (GB 26), xia xi (GB43) |

Table 1: The rules of acupoint-selection of acupuncture for PCOS.
3.1. Chinese Herbal Monomer Extracts

3.1.1. Berberine. Berberine is a quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids. It can be found in plants such as *Berberis*, *Berberis aquifolium* (Oregon grape), and *Berberis vulgaris* (barberry) [40, 41]. Several studies have already reported about berberine on PCOS and summarized its mechanism including lowering blood glucose, improving IR, decreasing androgen, and affecting lipid metabolism. Meanwhile, a meta-analysis drew a conclusion that berberine showed a promising prospect in treating PCOS-IR [42].

Animal experiments showed that berberine could reduce blood glucose and improve IR by activating the PI3K/AKT pathway and inhibiting the upregulation of the MAPK pathway and glucose transporter 4 (GLUT4) [43, 44]. Zhang et al. [45] found that berberine could decrease the level of IR in PCOS-like rats by improving GLUT4, which can regulate both the PI3K/AKT and MAPK pathways. Another animal experiment conducted by Feng L et al. also confirmed that berberine could effectively decrease the blood supply and angiogenesis of ovarian tissue and improve the morphology of ovarian tissue in PCOS rats [46]. Zhang et al. [47] made a study on 20 rats to observe the mechanism of berberine on PCOS. The study confirmed that berberine could improve abnormal glucose and lipid metabolism in PCOS-like rats and regulate the level of serum steroid hormones. Berberine plays a vital role in the treatment of PCOS-related reproductive disorders. Studies about the mechanism of berberine pointed out that it could improve the gene level, upregulate the expression of ovarian CYP19a1 gene and uterine Glut4 gene, and downregulate the expression of ovarian CYP17a1 gene.

3.1.2. Cryptotanshinone. Cryptotanshinone is extracted from danshen root, a Chinese herb. Studies have shown that it can significantly improve the abnormal glucose and lipid metabolism and hyperandrogenemia and can reduce the inhibitory effect of PI3K inhibitor LY294002 on the PI3K pathway in cerebral cortex nerve tissue, thereby protecting the activity of nerve cells, which may be the mechanism of cryptotanshinone in treating PCOS [48].

An animal experiment conducted by Kuang HY showed that cryptotanshinone could significantly reduce the capability of PCOS mice to modulate glucose levels in response to varying diets; meanwhile, it could increase the phosphorylation level of key molecules in the PI3K signaling pathway of ovarian granulosa cells that reduced the ovarian volume of PCOS rats. The expression levels of steroid hormone synthase STAR and CYP17 in rat granulosa cells can improve hyperandrogenism [49]. Another rat experiment showed that cryptotanshinone improved abnormal glucose and lipid metabolism in PCOS rats and reduced LH and T levels to restore the estrous cycle and ovulation of rats [50]. Studies have suggested that the effect of cryptotanshinone on PCOS may be achieved by downregulating the expression of the CYP17 gene and IR [51]. Wu et al. [52] randomized 72 PCOS patients into the observation group (36 cases) and the control group (36 cases). The observation group took Diane-35 combined with a Tanshinone capsule, while the control group was given Diane-35 merely. After 3 months, TG, TC, LDL-C, TSH, LH, ACTH, β-EP, Cor, and UFC were all improved. It is concluded that the Tanshinone capsule could improve the lipid metabolism of PCOS patients and regulate the function of the HPOA.

3.1.3. Other Chinese Medicine Monomers. The total flavonoids of Cuscuta are extracted from the herbal medicine Cuscuta. Studies have shown that the total flavonoids of Cuscuta can reduce the ovarian index of PCOS-like rats and alleviate the proliferation; meanwhile, it can also restore the HPOA function by regulating the secretion of estrogen and androgen and inhibiting the expression of ovarian apoptotic proteins [53, 54]. Glycyrrhetinic acid, a main component of the traditional Chinese medicine licorice, can treat PCOS due to its anti-inflammatory, analgesic, antiallergic, etc. properties. Studies have indicated that the mechanism of glycyrrhetinic acid in treating PCOS lies in the fact that it can enhance insulin sensitivity and reduce testosterone in PCOS patients. In addition, glycyrrhetinic acid can increase the expression of AMPK mRNA in porcine ovarian granulosa cells and reduce the androgen secretion capacity of insulin-resistant granulosa cells and the level of CYP17 mRNA [55, 56]. Silymarin is extracted from the dried fruits of the Compositae plant *Silybum marianum*. Studies have found that both glycyrrhetinic acid and silibinin can increase the expression level of AMPK mRNA and reduce the androgen secretion capacity and CYP17 mRNA of insulin-resistant granule cells [57].

In summary, considerable trials have verified the effectiveness of Chinese medicine monomers on PCOS and concluded that its mechanism may be related to improving IR, reducing androgen level, regulating lipid metabolism, etc. However, the existing studies on PCOS by Chinese medicine monomers still lack persuasiveness due to some inevitable factors. Therefore, more high-quality research studies are needed to add weight to its efficacy in PCOS.

3.2. Chinese Herbal Formulas. Compared with other CAMs, formulas are the most commonly used in China. However, compared with the remarkable efficacy of formulas, the explanation of its mechanism lacks unified evidence. Therefore, the existing mechanisms of formulas in treating PCOS are still not convincing and need to be confirmed by further studies. A review about formulas in treating PCOS showed that several herbs were beneficial in improving menstrual and ovulatory dysfunctions, obesity, IR, lipid metabolism dysfunction, and androgen excess-related conditions [58]. Based on one study, the treatment of PCOS with formulas may correct the abnormal secretion of endocrine hormones and improve glucose and lipid metabolism, etc., thereby improving ovarian morphology and pregnancy outcome [59]. The usual clinical formulas mainly include Cangfu daotan Decoction, Xiaoyao San, Jiawei Xiaoyao San, and Danggui Shaoyao San. The composition of
Evidence-Based Complementary and Alternative Medicine

these formulas is listed in Table 2. The following content describes the treatment of PCOS individually [60].

3.2.1. Cangfu Daotan Decoction (CDD). Cangfu Daotan decoction (CDD) is used for PCOS patients, especially the patients who are the type of stagnation of phlegm and dampness. According to a rat trial conducted by Yi about CDD on obesity-type PCOS, the result showed that CDD decreased the serum levels of TCHO, TG, LDL-c, LH, T, IL-1β, IL-6, and TNF-α and increased the levels of HDL-c, FSH, and E2 in a dose-dependent manner. Meanwhile, CDD could induce the expression of OATP2B1 and OATP3A1 in ovarian and uterine tissues. Therefore, CDD could improve pregnancy outcomes [61]. Zhang and Wu [62] analyzed that the mechanism of CDD in the treatment of PCOS is to improve IR. Fan and Ling [63] randomly assigned 60 cases of obese PCOS infertility patients into two groups each of 30 cases. Both groups were given oral letrozole and progesterone, and the treatment group was given CDD on this basis. The results showed that the pregnancy rates in the treatment group and control group were 53.33% and 26.67%, respectively, with a significant difference (P < 0.05). In addition, it also has obvious advantages in increasing the diameter of HCG follicles and the thickness of the endometrium.

3.2.2. Xiao Yao San (XYS). Xiao Yao San (XYS) is a traditional Chinese formula that is widely used for treating gynecological disease, especially for patients with liver constraint type PCOS. The results of animal experiments by Sun et al. showed that the mechanism of XYS treatment of PCOS may ameliorate chronic unpredictable mild stress-induced irregular estrous cycles and follicles development abnormalities, a decrease of estradiol and progesterone level as well as the increase of luteinizing hormone in serum, reduce cystic follicles formation and the apoptosis and autophagy of granulosa cells, and attenuate the increase in dopamine beta-hydroxylase and c-fos level in locus coeruleus, the noradrenaline level in serum and ovarian tissue, and the expression of beta 2 adrenergic receptor in ovarian tissue. Besides, XYS alleviated the reduction of phosphorylation of ribosomal protein S6 kinase polypeptide I and protein kinase B, as well as the increase of microtubule-associated protein light chain 3-1 to microtubule-associated protein light chain 3-II conversion both in vivo and in vitro [64].

3.2.3. Jiawei Xiao Yao San (JWXYS). Jiawei Xiaoyao San (JWXYS), also called Danzhi Xiaoyao San, is composed of 10 herbs, which is the most common herbal formula used for PCOS [65]. Wang [66] made an RCT to observe the effectiveness of JWXYS. 128 patients with PCOS were randomly assigned into two groups with 64 cases in each group. The control group received Ethinylestradiol cypionate, and the treatment group was combined with JWXYS based on it. The results showed that, compared with the control group, the E2, LH, and endometrial thickness can be improved significantly in the treatment group. An animal experiment reached the same conclusion either.

3.2.4. Danggui Shaoyao San (DSS). Danggui Shaoyao San (DSS), created by Zhang Zhongjing, has been a common Chinese herbal formula, which was used since the Han dynasty. Jia and Nie [67] randomized 90 PCOS patients into the treatment group (47 cases) and the control group (43 cases). DSS was prescribed to treatment group patients, while the control group was given gonadotropin. After 6 months, the total effective rate was 85.1% and 55.8%, respectively. The results of an RCT made by Chen and Xue [68] showed that DSS could improve the sex hormones (LH, FSH) and adjust the menstrual cycle.

3.2.5. Other Chinese Herbal Formulas. In addition to the commonly used Chinese herbal formula for treating PCOS mentioned above, some other formulas have been reported to be effective in PCOS. A rat study demonstrated that the underlying mechanism of Guizhi Fuling Wan in improving IR in PCOS-like rats is to regulate intestinal flora to control inflammation [69]. Heqi San, a traditional Chinese herbal formula, has been reported to regulate hormone levels in PCOS patients with metabolic disease, which may be an alternative application for treating PCOS. Zhao et al. [70] concluded through animal experiments that the beneficial effects of Heqi San on PCOS include altering serum hormone levels, recovering ovary morphological lesions, and improving IR, which are mediated through the PI3K/AKT pathway. Besides, Bushen Culuan Decoction (CCBCD) could effectively treat infertility patients with PCOS, according to a protocol of systematic review [71].

4. Dietary Supplements

4.1. Vitamin A. Vitamin A is a fat-soluble vitamin, also called retinol. Vitamin A-derived metabolites, such as retinoic acid and retinol, contribute to antioxidant activity and steroid metabolism, promote nuclear maturation of oocytes, and inhibit cell apoptosis [72–74]. A study [75] has shown that genes related to retinoic acid synthesis are expressed differently in intermembranous cells isolated from PCOS patients. A study made by Wickenheisser JK [76] showed that the use of retinol derivatives in the endometrial cells of PCOM and healthy women found that all intermembranous cells treated with trans-retinol increased dehydroepiandrosterone expression. Meanwhile, obesity and abnormal glucose metabolism are associated with retinol-binding protein 4 (rbp4) in overweight PCOS patients [77]. Another study reported that rbp4 was expressed in PCOS subcutaneous and omental adipocytes, and the rbp4 gene was upregulated, leading to changes in gonads and adrenal steroids [78].

4.2. Vitamin B. At present, many studies have found that vitamin B6, vitamin B12, and folic acid, which are related to homocysteine, are expressed at higher levels in PCOS
patients. The reason is that homocysteine is a sulfhydryl amino acid, mainly derived from dietary methionine. Studies have pointed out that elevated HCY will increase the risk of long-term complications such as cardiovascular and reproductive symptoms in patients with PCOS [79, 80]. Folic acid, vitamin B6, and vitamin B12 play an important role in regulating homocysteine. It has been reported that in the pathophysiologic study of PCOS, IR and HCY are positively correlated [81, 82]. Kaya et al. [83] confirmed that vitamin D is a significant and independent factor predicting IR, and vitamin D status is closely related to the decrease of vitamin B12. Regular exercises can reduce the concentration of HCY [84]. Metformin, a sensitizer for IR, is a commonly used medicine for the treatment of PCOS. Metformin has a good effect on regulating IR, and it will reduce the levels of vitamin B12 and folic acid in the body during the treatment [85]. The elevated homocysteine levels increase the risk of cardiovascular disease in patients with PCOS.

Inositol, one of the B vitamins, is a water-soluble vitamin. Like choline, it is a lipophilic vitamin. An experiment conducted by Minozzi et al. suggested that combined contraceptives and inositol may be more effective than OCP alone in controlling the endocrine, metabolism, and clinical manifestations of patients with PCOS and may reduce insulin levels and insulin resistance [86]. Another study carried out by Genazzani et al. demonstrated that after 2 weeks of MYO administration in patients with PCOS, plasma LH, PRL, T, insulin, and LH/FSH levels were significantly reduced. All subjects with amenorrhea and oligomenorrhea resumed their menstrual cycle [87].

4.3. Vitamin D. Vitamin D, apart from the most well-known nonskeletal functions, has a potential role in glucose homeostasis which is connected with the secretion of insulin by pancreatic beta cells, IR in different tissues, and its influence on systemic inflammation [88]. Krul-Poel et al. [89] have confirmed that vitamin D is a significant and independent factor predicting IR, and vitamin D status is closely related to the metabolic disorder of PCOS. Other research studies showed that women with PCOS often lack vitamin D, and its concentration was lower in patients with abdominal obesity. In overweight/obese people with PCOS, vitamin D is related to fasting blood glucose and HOMA [90]. Vitamin D supplementation can reduce abnormally elevated serum AMH levels, and the reduction of serum AMH levels may improve follicular formation by reducing androgens in the ovaries of women with PCOS and increasing the sensitivity of follicles to FSH [91]. However, there are some controversial reports. After vitamin D treatment for 11 patients with PCOS for 3 weeks, there has a good effect on IR, but there is no significant change in the levels of dehydroepiandrosterone, total testosterone, free testosterone, and androstenedione [92]. Meanwhile, a recent study showed that vitamin D supplementation and low-calorie diet did not change androgen levels in overweight and obese women with PCOS, but the menstrual frequency was significantly improved.

4.4. Vitamin E. Vitamin E as a lipid-soluble substance with nonenzymatic antioxidant properties, also known as tocopherol, which can effectively reverse the adverse influence by oxidative stress brought to the reproductive system and endocrine system, is widely used in the field of reproductive medicine [94, 95]. Vitamin E plays a vital role in the entire reproductive process. It can antagonize the oxidative stress caused by oxygen free radicals and antioxidation imbalance and regulate the normal physiological functions of the reproductive system [96]. The combined treatment of magnesium and vitamin E for PCOS for 12 weeks has benefits for hirsutism, serum hs-CRP, plasma NO, and TAC levels [97]. Extensive research papers have proven that the treatment of vitamin E in patients with PCOS has a significant effect [98, 99]. It can significantly reduce TG and serum total cholesterol and improve IR, T, and free testosterone index in patients with PCOS. In addition, new evidence confirms that vitamin E can improve the endometrial thickness of patients with unexplained infertility but does not support the hypothesis that vitamin E can increase the ovulation rate and pregnancy rate in PCOS [100].

5. Tai Chi, Yoga, and Qigong

Tai Chi, a unique Chinese exercise, combines physical activity and breathing organically, allowing people to enjoy a pleasant mood while exercising. The key point of Tai Chi is concentration and slow movements. Therefore, it is suitable for the elderly with a weak constitution and chronic diseases [101]. In 2012, NEJM published an article on the treatment of Parkinson’s with Tai Chi. The results confirmed that Tai Chi can alleviate the balance disorder of patients with mild to moderate Parkinson’s disease, improve functional ability, and reduce falls [102]. Tai Chi can maintain the harmony of qi and blood and regulate the balance of yin and yang, which can significantly reduce BMI; risk factors reduce...
cardiovascular disease and improve psychological health [103–105]. Studies have shown that Tai Chi is effective for long-term complications such as obesity, cardiovascular disease, diabetes, and psychological diseases caused by PCOS [106, 107]. Meng [108] summarized that Tai Chi can promote the metabolism of cells and tissues, increase the body’s utilization of glucose, the responsiveness of target cells, and the body’s tolerance to glucose, prevent the composition of HbA1c, and accelerate the combination of hemoglobin and oxygen to further control blood glucose, thereby reducing the levels of FBG, HbA1c, and 2hPBG. Paul-Labrador et al. [109] believed that Tai Chi can inhibit the activation of sympathetic nerves to improve the neutral-mediated vasodilatation of blood glucose control and reduce the glucose transport and uptake of skeletal muscle, while Tai Chi can reduce IR [110].

Yoga, a form of holistic mind-body medicine developed thousands of years ago, is a low-impact exercise that can help people maintain balance among physical, psychological, mental, sentimental, and spiritual aspects of life [111]. As a branch of CAM, it is used to treat many different diseases, such as hypertension, asthma, low back pain, arthritis and pain, stress management, and PCOS [112]. A study has shown that yoga can help control endocrine function and relieve symptoms of PCOS [113]. Compared with aerobic exercise, yoga will not cause any harm to the female reproductive system, at the same time, with the low-cost and feasible operation, so it is very promising to reduce the risk of PCOS through yoga [114]. An RCT conducted by Nidhi et al. found that yoga was more effective than conventional physical exercises in improving glucose, lipid, and insulin values, including IR values, in adolescent girls with PCOS [115]. Meanwhile, Patel et al. confirmed through RCT that regular yoga practice could reduce serum androgen in PCOS patients, which is a useful complementary therapy [112]. In addition, Ram Nidhi et al. found that a 12-week holistic yoga program was significantly better than a physical exercise program in reducing anxiety symptoms for adolescents with PCOS [116]. Ratnakumari et al. also reached a similar conclusion that yoga is efficient in bringing about beneficial changes in polycystic ovarian morphology and speculated that a longer intervention might require to regulate menstruation [117].

Although Qigong existed for thousands of years, it has never been widely adopted. In the early 1950s, Qigong became popular after Liu Guizhen advocated it. Medical Qigong, a specific form of Qigong, may have the effects of decreasing blood glucose, triglycerides, total cholesterol, body weight, BMI, and IR in type 2 diabetes in empirical and randomized controlled pilot studies [118]. An RCT conducted by Liu X has proved that after intervention by Qigong, the weight, waist circumference, leg strength, and IR improved which indicated weight reduction in the control of diabetes. Besides, a meta-analysis by Meng suggested that Qigong can improve the blood glucose of type 2 diabetes patients and benefit the management of it [119]. Owing to the fact that PCOS has the risk of obesity and cardiovascular disease, etc., we speculate that Qigong also has a certain effect in the treatment of PCOS [120].

6. Meditation Stress Reduction

Patients with PCOS are troubled by obesity, hirsutism, acne, irregular menstruation, and infertility, which affects their psychological health, physical condition, and quality of life to varying degrees [121]. The risk of anxiety and depression was significantly increased in patients with PCOS. Relevant research showed that more than 60% of PCOS patients were diagnosed with at least one kind of mental disorder [122]. The severity of depression, anxiety, obsessive-compulsive disorder, and somatization disorder measured by different scales in PCOS patients was higher than that in women without PCOS [123].

Emotional depression activates the neuroendocrine stress response system and simultaneously alters the immune function, leading to changes in brain structure [124, 125] and activity [126, 127]. Many people use meditation to relieve stress and treat stress-related diseases. Meditative stress reduction (MBSR) can help patients reduce emotional symptoms (e.g., anxiety, depression, and stress) and improve physical symptoms (e.g., pain) to a certain extent [128]. In addition, MBSR can reduce blood pressure, blood glucose, and inflammation [129–131]. These changes were due to improved autonomic nervous system and HPOA function after MBSR treatment [127, 132, 133]. Through MBSR treatment, PCOS patients’ risk of diabetes and cardiovascular disease will eventually be reduced. Takahashi et al. [134] conducted a study on quantitatively analyzed changes in psychophysiological parameters during Zen meditation. Their findings can be an important clue to the efficient use of meditation as a therapeutic procedure. Since most of the current trials on meditation in the treatment of PCOS are small-scale, nonrandomized studies, more large-scale trials are needed to prove its efficacy on PCOS [135].

7. Conclusions

PCOS is a reproductive endocrine disease closely related to infertility, obesity, diabetes, cardiovascular disease, and other metabolic diseases, accompanied by different degrees of psychological disorders. CAM for PCOS mainly includes acupuncture, Chinese medicine, diet and nutrition, Tai Chi, yoga, Qigong, and meditation. Through these therapies, the incidence of cardiovascular disease and diabetes can be reduced, and anxiety and depression can be relieved as well, therefore improving the quality of life. Although CAM has been used in some countries and regions, the globalization of CAM has been hindered due to the lack of more clear research on its safety and mechanism. The specific obstacles include the following: (1) there is a lack of a larger sample size and more structured methods to evaluate the safety and pharmacological mechanism of TCM; (2) there is not enough convincing evidence to support the efficacy or safety of dietary supplements; (3) there is a lack of verification of Taijiquan, yoga, meditation, and other interventions; (4) the molecular mechanism of some CAM therapies remains to be further studied and confirmed [136]. In the future, we need larger samples and RCTs to confirm the efficacy and safety of
CAM in the treatment of PCOS to provide a new method for PCOS.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Li-Yan Jia, Jia-Xing Feng, and Juan-Li Li contributed equally to this work.

Acknowledgments

The study was supported by the National Natural Science Foundation of China (grant no. 82074484) and the scientific research projects of the Heilongjiang Administration of Traditional Chinese Medicine (grant no. ZHY2020-134).

References

[1] R. Azziz, K. Kintziger, R. Li et al., “Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource,” Human Reproduction, vol. 34, no. 11, pp. 2254–2265, 2019.

[2] S. Vagios, K. E. James, C. R. Sacha et al., “A patient-specific model combining antimullerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders,” Fertility and Sterility, vol. 115, no. 1, 2021.

[3] R. Azziz, “Polycystic ovary syndrome,” Obstetrics & Gynecology, vol. 132, no. 2, pp. 321–336, 2018.

[4] E. A. Coutinho and A. S. Kauffman, “The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS),” Medical Sciences (Basel, Switzerland), vol. 7, no. 8, 2019.

[5] M. A. Gadalla, R. J. Norman, C. T. Tay et al., “Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome: an overview of systematic reviews,” International Journal of Fertility & Sterility, vol. 13, no. 4, pp. 257–270, 2020.

[6] H. Zhang, D. Li, R. Li, Z. Huo, and J. Qiao, “Treatment of polycystic ovary syndrome with acupuncture,” Acupuncture in Medicine, vol. 36, no. 4, p. 269, 2018.

[7] H. Yao and G. Yao, “Progress in the treatment of polycystic ovary syndrome with traditional Chinese medicine,” West. Chinese Med, vol. 32, no. 12, pp. 144–147, 2019.

[8] H. Guo and W. Zhang, “Overview of the application of acupuncture and moxibustion in the treatment of polycystic ovary syndrome,” Hunan Journal of Chinese Medicine, vol. 35, no. 10, pp. 184–186, 2019.

[9] H. Chen and C. E. D. Lim, “The efficacy of using acupuncture in managing polycystic ovarian syndrome,” Current Opinion in Obstetrics & Gynecology, vol. 31, no. 6, pp. 428–432, 2019.

[10] Y. Peng, X. Yang, X. Luo et al., “Novel mechanisms underlying anti-polycystic ovary-like syndrome effects of electroacupuncture in rats: suppressing SREBP1 to mitigate insulin resistance, mitochondrial dysfunction and oxidative stress,” Biological Research, vol. 53, no. 1, p. 50, 2020.

[11] J. Jo, Y. J. Lee, and H. Lee, “Acupuncture for polycystic ovarian syndrome: a systematic review and meta-analysis,” Medicine (Baltimore), vol. 96, no. 23, p. e7066, 2017.

[12] L. Zhang, Therapeutic Effect and Mechanism of Acupuncture on Polycystic Ovary Syndrome in Rats, Huazhong University of Science and Technology, Wuhan, China, 2010.

[13] Y. Peng, Y. Zhang, S. Wang et al., “Discussion on acupuncture treatment of polycystic ovary syndrome based on intestinal flora,” Journal of Clinical Acupuncture and Moxibustion, vol. 35, no. 3, pp. 1–5, 2019.

[14] C. Ee, C. A. Smith, M. Costello et al., “Acupuncture or auricular electro-acupuncture as adjuncts to lifestyle interventions for weight management in PCOS: protocol for a randomised controlled feasibility study,” Pilot Feasibility Studies, vol. 6, p. 53, 2020.

[15] D. Wu, X. Wang, H. Cong, S. Liu, and Y. Liang, “The effect of acupuncture on ovarian function in obese patients with polycystic ovary syndrome,” World Chinese Medicine, vol. 15, no. 16, pp. 2482–2485, 2020.

[16] R. Huang, X. Li, S. Xu et al., “Acupoint injection treatment for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials,” Annals of Palliative Medicine, vol. 8, no. 5, 2019.

[17] C. Jin, R. Pang, L. Xu, Z. Wu, and J. Zhao, “Acupuncture and moxibustion treatment of polycystic ovary syndrome clinical selection of points and prescription rules,” Journal of Chinese Acupuncture, vol. 35, no. 6, pp. 625–630, 2015.

[18] L. Ren, Acupuncture and Moxibustion in the Treatment of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Beijing University of Chinese Medicine, Beijing, China, 2014.

[19] C.-C. Yu, L.-H. Kong, C.-Y. Ma et al., “The rules of acupoint-selection of acupuncture for polycystic ovary syndrome based on data mining,” World Journal of Acupuncture-Moxibustion, vol. 26, no. 3, pp. 73–78, 2016.

[20] F. Qu, R. Li, W. Sun et al., “Use of electroacupuncture and transcutaneous electrical acupoint stimulation in reproductive medicine: a group consensus,” Journal of Zhejiang University. Science. B, vol. 18, no. 3, pp. 186–193, 2017.

[21] G. Xu, A.-D. Zhang, X. Wang, J.-D. Liu, J.-W. Feng, and Y.-L. Chen, “Effect of electroacupuncture at different acupoints on follicle development and related factors in serum and ovary tissues of PCOS rats,” Acupuncture research, vol. 44, no. 10, 2019.

[22] Y. Shi, L. Li, J. Zhou et al., “Efficacy of electroacupuncture in regulating the imbalance of AMH and FSH to improve follicle development and hyperandrogenism in PCOS rats,” Biomedicine & Pharmacotherapy, vol. 113, 2019.

[23] Y. Peng, L. Guo, A. Gu et al., “Electroacupuncture alleviates polycystic ovary syndrome-like symptoms through improving insulin resistance, mitochondrial dysfunction, and endoplasmic reticulum stress via enhancing autophagy in rats,” Molecular Medicine, vol. 26, no. 1, p. 73, 2020.

[24] U. R. Budhastuti, E. Melinawati, S. Sulistyorawati, and I. Nurwati, “Electroacupuncture effect on polycystic ovary syndrome to improve oocytes’ growth,” Medical Acupuncture, vol. 31, no. 6, pp. 379–383, 2019.

[25] Y. Li, Clinical Study of Electroacupuncture on the Quality of Follicular Fluid LIF and Egg Cells in PCOS Patients with IVF-ET Cycle, Shandong University of Traditional Chinese Medicine, Jinan, China, 2011.

[26] W. Cui, J. Li, W. Sun, and J. Wen, “Effects of electroacupuncture on the quality of egg cells and pregnancy in patients with polycystic ovary syndrome during in vitro fertilization and embryo transfer,” Chinese Acupuncture and Moxibustion, vol. 31, no. 8, pp. 687–691, 2011.
Evidence-Based Complementary and Alternative Medicine

[27] J. Sheng, X. Jin, J. Zhu, Y. Chen, and X. Liu, “The effectiveness of acupoint catgut embedding therapy for abdominal obesity: a systematic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 9714313, 12 pages, 2019.

[28] Y. Lin, The Effect of Acupoint Catgut Embedding on Reproductive Endocrine and Insulin Resistance in PCOS-IR Model Rats, Guangzhou University of Chinese Medicine, Guangzhou, China, 2016.

[29] W. Wang, The Effect of Acupoint Catgut Implantation on Hyperandrogenemia in Patients with Polycystic Ovary Syndrome, Shandong University of Chinese Medicine, Jinan, China, 2013.

[30] C. Yu, G. Yao, Y. Zhou, and L. Kong, “Study on the rule of clinical point selection for the treatment of polycystic ovary syndrome with catgut embedding at acupoints,” Journal of Clinical Acupuncture and Moxibustion, vol. 32, no. 11, pp. 73–76, 2016.

[31] X. Lin, M. Liu, Z. Ren, Z. Fu, and L. Fu, “Efficacy observation on 30 cases of polycystic ovary syndrome treated with warm needle moxibustion,” Human Journal of Traditional Chinese Medical Sciences, vol. 31, no. 4, pp. 94–95, 2015.

[32] C. Xu and Y. Mu, “The effect of Dumai warming acupuncture combined with clomiphene in the treatment of infertility caused by polycystic ovary syndrome,” Journal of Traditional Chinese Medical Sciences, vol. 35, no. 4, pp. 2153–2156, 2020.

[33] M. Gu, Study on the Effect of Warming Acupuncture on Improving PCOS Oxidative Stress and its Correlation with Obesity, Nanjing University of Traditional Chinese Medicine, Nanjing, China, 2018.

[34] Y. Li, L. Hou, Y. Wang et al., “Auricular points acupuncture for insulin resistance in overweight/obese women with polycystic ovary syndrome: protocol for a randomised controlled pilot trial,” BMJ Open, vol. 9, no. 5, 2019.

[35] F. Gao, “Clinical study on anovulatory infertility caused by polycystic ovary syndrome by pressing beans at ear points,” Chinese Medical Journal, vol. 4, no. 24, pp. 214–215, 2009.

[36] S. Zhang, H. He, W. Gao, X. Wu, and D. Zhang, “Mechanism of transcutaneous auricular vagus nerve stimulation on polycystic ovary syndrome,” Acupuncture Research, vol. 4, no. 52, pp. 164–168, 2020.

[37] C. Wang and X. Liang, “The mechanism of insulin resistance in polycystic ovary syndrome and the progress of traditional Chinese medicine intervention,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 39, no. 7, pp. 894–896, 2019.

[38] M. Zhang, L. Hou, and Y. Liu, “Research progress of traditional Chinese medicine in the treatment of insulin resistance in polycystic ovary syndrome,” World Journal of Integrated Traditional and Western Medicine, vol. 11, no. 3, pp. 436–439, 2019.

[39] Y. Li, H. Ma, Y. Zhang et al., “Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial,” Trials, vol. 14, no. 1, p. 226, 2013.

[40] A. F. G. Cicero and A. Baggioni, “Berberine and its role in chronic disease,” Advances in Experimental Medicine and Biology, vol. 928, pp. 27–45, 2016.

[41] H. Chang and X. Wu, “The effect of berberine on PCOS and the research progress of related mechanisms,” Obstetrics and Gynecology, vol. 26, no. 3, pp. 235–237, 2017.

[42] Z. Li, X.-M. Zhou, and X.-L. Li, “The effect of berberine on polycystic ovary syndrome patients with insulin resistance (PCOS-IR): a meta-analysis and systematic review,” Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 2532935, 8 pages, 2018.

[43] M. Wang, S. Zhang, W. Tian et al., “The effect of berberine on key proteins of insulin resistance pathway in PCOS rats,” Jilin Academy of Traditional Chinese Medicine, vol. 39, no. 7, pp. 925–929, 2019.

[44] H. Kuang, Y. Wang, M. Wang et al., “The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome,” PLOS One, vol. 15, no. 8, 2020.

[45] N. Zhang, X. Liu, L. Zhuang et al., “Berberine decreases insulin resistance in a PCOS rats by improving GLUT4 dual regulation of the PI3K/AKT and MAPK pathways,” Regulatory Toxicology and Pharmacology, vol. 110, 2020.

[46] L. Feng, M. Kong, J. Zhang, X. Xu, and Y. Qi, “Effects of berberine on blood supply of ovaries in rats with polycystic ovary syndrome,” World Chinese Medicine, vol. 15, no. 20, pp. 3055–3057, 2020.

[47] Y. Zhang, W. Zhao, Y. Han et al., “Therapeutic effect of berberine on rats with phlegm-dampness polycystic ovary syndrome and its mechanism,” Journal of Traditional Chinese Medical Sciences, vol. 17, no. 8, pp. 1807–1812, 2019.

[48] F. Zhang, W. Zheng, R. Pi et al., “Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway,” Experimental Brain Research, vol. 193, no. 1, pp. 109–118, 2009.

[49] H. Kuang, K. Ma, W. Li et al., “Study on the mechanism of cryptotanshinone regulating the reproductive endocrine function of ovarian granulosa cells in PCOS model rats,” Journal of Traditional Chinese Medicine, vol. 45, no. 5, pp. 40–44, 2017.

[50] N. Wang, “Effects of cryptotanshinone on glucose and lipid metabolism and sex hormones in rats with polycystic ovary syndrome,” Maternal and Child Health in China, vol. 30, no. 20, pp. 3490–3493, 2015.

[51] J. Yu, Z. Wang, L. Zhou et al., “Cryptotanshinone improves polycystic ovary syndrome hyperandrogenemia by down-regulating the expression of CYP17 gene and IR,” Journal of Traditional Chinese Medicine, vol. 29, no. 5, pp. 1699–1705, 2014.

[52] M. Wu, N. Liu, and L. Han, “Effects of Tanshinone capsules on lipid metabolism and hypothalamus-pituitary-adrenal Axis in patients with polycystic ovary syndrome,” Shandong University, vol. 56, no. 32, pp. 94–96, 2016.

[53] M. Miao, M. Peng, X. Yan et al., “Effects of total flavonoids of Cuscuta on letrozole-induced polycystic ovary syndrome rat model,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 25, no. 16, pp. 17–23, 2019.

[54] X. Yan, Effect of Total Flavonoids of Cuscuta Seeds on Rat Model of Polycystic Ovary Syndrome, Henan University of Chinese Medicine, Zhengzhou, China, 2018.

[55] M. Tian, W. Li, Y. Guo et al., “Research progress on the treatment of insulin resistance in polycystic ovary syndrome with Chinese medicine monomer,” World Integrated Traditional Chinese and Western Medicine, vol. 11, no. 9, pp. 1326–1328+1332, 2016.

[56] D. Armanini, R. Castello, C. Scaroni et al., “Treatment of polycystic ovary syndrome with spironolactone plus licorice,” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 131, no. 1, 2007.

[57] W. Li, X. Ji, J. Cong, and X. Wu, “Effects of glycyrrhetinic acid and silybin on insulin-resistant pig ovarian granulosa
cells cultured in vitro,” *Revue Scientifique et Technique*, vol. 29, no. 19, pp. 66–69, 2011.

[58] A. Moini Jazani, H. Nasimi Doost Azgomi, A. Nasimi Doost Azgomi, and R. Nasimi Doost Azgomi, “A comprehensive review of clinical studies with herbal medicine on polycystic ovary syndrome (PCOS),” *DARU Journal of Pharmaceutical Sciences*, vol. 27, no. 2, pp. 863–877, 2019.

[59] X. Y. Zhou, L. Zhou, and Z. Y. Sun, “Research progress in mechanism of traditional Chinese medicine treatment of polycystic ovary syndrome,” *Zhongguo Zhongya Zazhi*, vol. 41, no. 20, pp. 3715–3720, 2016.

[60] W.-T. Liao, J.-H. Chiang, C.-J. Li et al., “Investigation on the use of traditional Chinese medicine for polycystic ovary syndrome in a nationwide prescription database in Taiwan,” *Journal of Clinical Medicine*, vol. 7, no. 7, 2018.

[61] W. Yi, X. Li, K. Chen, M. Zhu, X. Cai, and A. Pan, “Effects of Cangfu Daotan Decoction on obese polycystic ovary syndrome and its mechanism,” *Steroids*, vol. 165, Article ID 108740, 2021.

[62] D. Zhang and X. Wu, “Analysis on mechanism of Cangfu Daotan decoction on insulin resistance in polycystic ovary syndrome,” *World Chinese Medicine*, pp. 1–5, 2020.

[63] J. Fan and N. Ling, “Clinical observation of modified can-gufudaotan decoction in treating PCOS ovulation dysfunction infertility,” *Journal of Liaoning College of Traditional Chinese Medicine*, pp. 1–8, 2020.

[64] H.-Y. Sun, Q. Li, Y.-Y. Liu et al., “Xiao-yao-San, a Chinese medicine formula, ameliorates chronic unpredictable mild stress induced polycystic ovary in rat,” *Frontiers in Physiology*, vol. 8, p. 729, 2017.

[65] M. Sun, X. Sun, W. G. Le, and J. Dong, “Intervention effect of Danzhi Xiaoyao San on polycystic ovary syndrome model rats,” *Sichuan Chinese Medicine*, vol. 37, no. 9, pp. 37–41, 2019.

[66] Q. Wang, “Clinical observation of Danzhi Xiaoyao San in the treatment of polycystic ovary syndrome with liver depression and blood heat,” *Chinese Medical Guidance*, vol. 18, no. 26, pp. 129–130, 2020.

[67] H. Jia and X. Nie, “Danggui Shaoyao powder in the treatment of 47 cases of polycystic ovary syndrome,” *Chinese Medical Journal*, vol. 52, no. 9, pp. 785–786, 2011.

[68] C. Chen and S. Xue, “Danggui Shaoyao San combined with Daying-35 in the treatment of polycystic ovary syndrome,” *Chinese Medical Journal*, vol. 30, no. 8, pp. 1511–1513, 2018.

[69] Y. Zhu, Y. Li, M. Liu, X. Hu, and H. Zhu, “Guizhi Fuling Wan, Chinese herbal medicine, ameliorates insulin sensitivity in PCOS model rats with insulin resistance via remodeling intestinal homeostasis,” *Frontiers in Endocrinology (Lausanne)*, vol. 11, p. 575, 2020.

[70] H. Zhao, D. Zhou, Y. Chen et al., “Beneficial effects of Hefi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway,” *Daru*, vol. 25, no. 1, p. 21, 2017.

[71] J. Feng, X.-F. Zhang, J.-N. Ren, Y.-H. Huang, and X. Zheng, “Efficacy of clomifene citrate combined Bushen Culuan decoction for the treatment of infertility caused by polycystic ovary syndrome: a protocol of systematic review,” *Medicine (Baltimore)*, vol. 99, no. 27, 2020.

[72] R. Khan, E. Stener-Victorin, X. Wu, and L. Legro, “The physiological basis of complementary and alternative medicines for polycystic ovary syndrome,” *American Journal of Physiology. Endocrinology and Metabolism*, vol. 301, no. 1, 2011.

[73] Y. Pu, Z. Wang, Y. Bian et al., “All-transretinoic acid improves goat oocyte nuclear maturation and reduces apoptotic cumulus cells during in vitromaturation,” *Animal Science Journal*, vol. 85, no. 9, pp. 833–839, 2014.

[74] G. K. Deb, S. R. Dey, J. I. Bang, J. G. Lee, and I. K. Kong, “9-cis Retinoic acid inhibits cumulus cell apoptosis during the maturation of bovine cumulus-oocyte-complexes,” *Journal of Animal Science*, vol. 90, no. 6, pp. 1798–1806, 2012.

[75] J. R. Wood, V. L. Nelson, C. Ho et al., “The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis,” *The Journal of biological chemistry*, vol. 278, no. 29, 2003.

[76] J. K. Wickenheisser, V. L. Nelson-DeGrave, K. L. Hendricks, R. S. Legro, J. F. Strauss, and J. M. McAllister, “Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 90, no. 8, pp. 4858–4865, 2005.

[77] S. Hahn, M. Backhaus, M. Broecker-Preuss et al., “Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism,” *European Journal of Endocrinology*, vol. 157, no. 2, 2007.

[78] B. K. Tan, J. Chen, H. Lehner, R. Kennedy, and H. S. Randeva, “Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroi-ds,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 92, no. 7, pp. 2764–2772, 2007.

[79] H. Yarali, A. Yildirir, F. Aybar et al., “Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome,” *Fertility and Sterility*, vol. 76, no. 3, pp. 511–516, 2001.

[80] M. de la Calle, R. Usandizaga, M. Sancha, F. Magdaleno, A. Herranz, and E. Cabrillo, “Homocysteine, folic acid and B-group vitamins in obstetrics and gynaecology,” *European Journal of Obstetrics & Gynecology and Reproductive Biology*, vol. 107, no. 2, pp. 125–134, 2003.

[81] L. Loverro, F. Lorusso, L. Mei, R. Depalo, G. Cormio, and L. Selvaggi, “The plasma homocysteine levels are increased in polycystic ovary syndrome,” *Gynecologic and Obstetric Investigation*, vol. 53, no. 3, 2002.

[82] A. Badawy, O. State, S. S. Abd El Gawad, and O. Abd El Aziz, “Plasma homocysteine and polycystic ovary syndrome: the missed link,” *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, vol. 131, no. 1, 2007.

[83] C. Kaya, D. Cengiz, and H. Satiroglu, “Obesity and insulin resistance associated with lower plasma vitamin B12 in PCOS,” *Reproductive Biomedicine Online*, vol. 19, no. 5, 2009.

[84] H. S. Randeva, K. C. Lewandowski, J. Drzewoski et al., “Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 87, no. 10, pp. 4496–4501, Oct. 2002.

[85] M. Minozzi, D. Costantino, C. Guaraldi, and V. Unfer, “The molecular biology of PCOS,” *Steroids*, vol. 165, Article ID BT_108740, 2021.

[86] B. K. Tan, J. Chen, H. Lehner, R. Kennedy, and H. S. Randeva, “Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 92, no. 7, pp. 2764–2772, 2007.
parameters in polycystic ovary syndrome,” *Gynecological Endocrinology*, vol. 27, no. 11, 2011.

[87] A. D. Genazzani, C. Lanzoni, F. Ricchieri, and V. M. Jasonni, “Myo-inositol administration positively affects hyper-insulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome,” *Gynecological Endocrinology*, vol. 24, no. 3, 2008.

[88] A. Muñoz-Garach, B. García-Fontana, and M. Muñoz-Torres, “Vitamin D status, calcium intake and risk of developing type 2 diabetes: an unresolved issue,” *Nutrients*, vol. 11, no. 3, 2019.

[89] Y. H. M. Krul-Poel, C. Snackey, Y. Louwers et al., “The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review,” *European Journal of Endocrinology*, vol. 169, no. 6, pp. 853–865, 2013.

[90] R. Pasquali, A. Gambineri, D. Biscotti et al., “Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 85, no. 8, pp. 2767–2774, 2000.

[91] M. Irani, H. Minkoff, D. B. Seifer, and Z. Merhi, “Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 99, no. 5, pp. E886–E890, 2014.

[92] H. Selimoglu, C. Duran, S. Kiyici et al., “The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome,” *Journal of Endocrinological Investigation*, vol. 33, no. 4, pp. 234–238, 2010.

[93] S. Jafari-Sidivajani, R. Ahangari, M. Hozoori, H. Mozaffari-Khosravi, H. Fallahzadeh, and A. Nadjarzadeh, “The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial,” *Journal of Endocrinological Investigation*, vol. 41, no. 5, pp. 597–607, 2018.

[94] H. M. Evans and K. S. Bishop, “On the existence of a Hitherto unrecognized dietary factor essential for reproduction,” *Science*, vol. 56, 1458 pages, 1922.

[95] J. T. Tarin, S. Pérez-Albalá, and A. Cano, “Oral antioxidants counteract the negative effects of female aging on oocyte quantity and quality in the mouse,” *Molecular Reproduction Development*, vol. 61, no. 3, 2002.

[96] J. Chen, Q. Guo, Y.-H. Pei et al., “Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: a retrospective cohort study,” *BMC Womens. Health*, vol. 20, no. 1, p. 69, 2020.

[97] M. Shokrpour and Z. Asemi, “The effects of magnesium and vitamin E Co-supplementation on hormonal status and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome,” *Biological Trace Element Research*, vol. 191, no. 1, 2019.

[98] A. Izadi, S. Shirazi, S. Taghizadeh, and B. P. Gargari, “Independent and additive effects of coenzyme Q10 and vitamin E on cardiometabolic outcomes and visceral adiposity in women with polycystic ovary syndrome,” *Archives of Medical Research*, vol. 50, no. 2, pp. 1–10, 2019.

[99] F. Ebrahimi, M. Samimi, F. Foroozanfard et al., “The effects of omega-3 fatty acids and vitamin E Co-supplementation on indices of insulin resistance and hormonal parameters in patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial,” *Experimental and Clinical Endocrinology & Diabetes*, vol. 125, no. 6, pp. 353–359, Jun. 2017.

[100] A. A. Morsy, N. A. Sabri, A. M. Mourad, E. M. Mojahed, and M. A. Shawki, “Randomized controlled open-label study of the effect of vitamin E supplementation on fertility in clophemine citrate-resistant polycystic ovary syndrome,” *Journal of Obstetrics and Gynaecology Research*, vol. 46, no. 11, pp. 2375–2382, 2020.

[101] Z. Zhou, R. Zhou, K. Li et al., “Effects of tai chi on physiology, balance and quality of life in patients with type 2 diabetes: a systematic review and meta-analysis,” *Journal of Rehabilitation Medicine*, vol. 51, no. 6, pp. 405–417, 2019.

[102] F. Li, P. Harmer, K. Fitzgerald et al., “Tai chi and postural stability in patients with Parkinson’s disease,” *New England Journal of Medicine*, vol. 366, no. 6, pp. 511–519, 2012.

[103] X. Yu, J. P. C. Chau, and L. Huo, “The effectiveness of traditional Chinese medicine-based lifestyle interventions on biomedical, psychosocial, and behavioral outcomes in individuals with type 2 diabetes: a systematic review with meta-analysis,” *International Journal of Nursing Studies*, vol. 80, pp. 165–180, 2018.

[104] Q. Song, Y. Yuan, C. Jiao, and X. Zhu, “Curative effect of Tai Chi exercise in combination with auricular plaster therapy on improving obesity patient with secondary hyperlipidemia,” *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 11, pp. 21386–21392, 2015.

[105] A. K. W. Chan, S. Y. Chir, D. T. R. Lee et al., “Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: a randomised controlled trial,” *International Journal of Nursing Studies*, vol. 88, 2018.

[106] Y. Li, C. Peng, G. Cao, W. Li, and L. Hou, “Tai chi for overweight/obese adolescent and young women with polycystic ovary syndrome: a randomized, placebo-controlled trial,” *Diabetes Care*, vol. 35, 2012.

[107] A. Yeung, J. S. M. Chan, J. C. Cheung, and L. Zou, “Qigong and tai-chi for mood regulation,” *Focus*, vol. 16, no. 1, pp. 40–47, 2018.

[108] M. Chao, C. Wang, X. Dong, and M. Ding, “The effects of tai chi on type 2 diabetes mellitus: a meta-analysis,” *Journal of Diabetes Research*, vol. 2018, Article ID 7350567, 9 pages, 2018.

[109] M. Paul-Labrador, D. Polk, J. H. Dwyer et al., “Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease,” *Archives of Internal Medicine*, vol. 166, no. 11, pp. 1218–1224, 2006.

[110] D. W. Dunstan, R. W. Daly, N. Owen et al., “High-intensity resistance training improves glycemic control in older patients with type 2 diabetes,” *Diabetes Care*, vol. 25, no. 10, 2002.

[111] R. Nidhi, V. Padmalatha, R. Nagarathna, and R. Amritanshu, “Effects of a holistic yoga program on endocrine parameters in adolescents with polycystic ovarian syndrome: a randomized controlled trial,” *The Journal of Alternative and Complementary Medicine*, vol. 19, no. 2, pp. 153–160, 2013.

[112] V. Patel, H. Menezes, C. Menezes et al., “Regular mindful yoga practice as a method to improve androgen levels in women with polycystic ovary syndrome: a randomized, controlled trial,” *The Journal of the American Osteopathic Association*, 2020.
[113] S. Shanthi, “Utilization of Swamiji Vethathri Maharishis Kayakalpa Yoga Practice for Women with PCOS,” Bharatiar University, Coimbatore, India, 2013.

[114] V. Selvaraj, J. Vanitha, F. M. Dhanaraj, P. Sekar, and A. R. Babu, “Impact of yoga and exercises on polycystic ovarian syndrome risk among adolescent schoolgirls in South India,” Health Science Reports, vol. 3, no. 4, p. e212, 2020.

[115] R. Nidhi, V. Padmalatha, R. Nagarathna, and A. Ram, “Effect of a yoga program on glucose metabolism and blood lipid levels in adolescent girls with polycystic ovarian syndrome,” International Journal of Gynecology & Obstetrics, vol. 118, no. 1, pp. 37–41, 2012.

[116] R. Nidhi, V. Padmalatha, R. Nagarathna, and R. Amritanshu, “Effect of holistic yoga program on anxiety symptoms in adolescent girls with polycystic ovarian syndrome: a randomized control trial,” International Journal of Yoga, vol. 5, no. 2, pp. 112–117, 2012.

[117] M. Ratnakumari, N. Manavalan, D. Sathyanath, Y. Ayda, and K. Reka, “Study to evaluate the changes in polycystic ovarian morphology after naturopathic and yogic interventions,” International Journal of Yoga, vol. 11, no. 2, pp. 139–147, 2018.

[118] A. L. Putiri, J. R. Close, H. R. Lilly, N. Guillaume, and G.-C. Sun, “Qigong exercises for the management of type 2 diabetes mellitus,” Medicine (Basel, Switzerland), vol. 4, no. 3, 2017.

[119] X. Liu, Y. D. Miller, N. W. Burton, J.-H. Chang, and W. J. Brown, “Qi-gong mind-body therapy and diabetes control,” American Journal of Preventive Medicine, vol. 41, no. 2, pp. 152–158, 2011.

[120] D. Meng, W. Chunyan, D. Xiaoosheng, and Y. Xiangren, “The effects of qigong on type 2 diabetes mellitus: a systematic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 8182938, 8 pages, 2018.

[121] N. Raja-Khan, K. Agito, J. Shah et al., “Mindfulness-based stress reduction for overweight/obese women with and without polycystic ovary syndrome: design and methods of a pilot randomized controlled trial,” Contemporary Clinical Trials, vol. 41, pp. 287–297, 2015.

[122] E. Stener-Victorin, M. Manti, R. Fornes, S. Risal, H. Lu, and A. Benrick, “Origins and impact of psychological traits in polycystic ovary syndrome,” Medicine Sciences (Basel, Switzerland), vol. 7, no. 8, 2019.

[123] C. Brutoel, F. Zaïem, M. Alsawas, A. S. Morrow, M. H. Murad, and A. Javed, “Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis,” Endocrine, vol. 62, no. 2, pp. 318–325, 2018.

[124] L. Witek-Janusek, K. Albuquerque, K. R. Chroniak, C. Chroniak, R. Durazo-Arvizu, and H. L. Mathews, “Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer,” Brain, Behavior, and Immunity, vol. 22, no. 6, pp. 969–981, 2008.

[125] B. K. Höfzel, U. Ott, T. Gard et al., “Investigation of mindfulness meditation practitioners with voxel-based morphometry,” Social Cognitive and Affective Neuroscience, vol. 3, no. 1, pp. 55–61, 2008.

[126] S. W. Lazar, C. E. Kerr, R. H. Wasserman et al., “Meditation experience is associated with increased cortical thickness,” Neuroreport, vol. 16, no. 17, 2005.

[127] J. C. Smith, “Alterations in brain and immune function produced by mindfulness meditation: three caveats,” Psychosomatic Medicine, vol. 66, no. 1, 2004.

[128] M. Goyal, S. Singh, E. M. S. Sibinga et al., “Meditation programs for psychological stress and well-being: a systematic review and meta-analysis,” JAMA Internal Medicine, vol. 174, no. 3, pp. 357–368, 2014.

[129] L. E. Carlson, M. Speca, P. Faris, and K. D. Patel, “One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients,” Brain, Behavior, and Immunity, vol. 21, no. 8, pp. 1038–1049, 2007.

[130] Y. Matchim, J. M. Armer, and B. R. Stewart, “Effects of mindfulness-based stress reduction (MBSR) on health among breast cancer survivors,” Western Journal of Nursing Research, vol. 33, no. 8, pp. 996–1016, 2011.

[131] S. Rosenzweig, D. K. Reibel, J. M. Greeno et al., “Mindfulness-based stress reduction is associated with improved glycemic control in type 2 diabetes mellitus: a pilot study,” Alternative Therapies in Health and Medicine, vol. 13, no. 5, pp. 36–38, 2007.

[132] Y. Kubota, W. Sato, M. Toichi et al., “Frontal midline theta rhythm is correlated with cardiac autonomic activities during the performance of an attention demanding meditation procedure,” Cognitive Brain Research, vol. 11, no. 2, pp. 281–287, 2001.

[133] M. Nagai, S. Hoshide, and K. Kario, “The insular cortex and cardiovascular system: a new insight into the brain-heart axis,” Journal of the American Society of Hypertension, vol. 4, no. 4, pp. 174–182, 2010.

[134] T. Takahashi, T. Murata, T. Hamada et al., “Changes in EEG and autonomic nervous activity during meditation and their association with personality traits,” International Journal of Psychophysiology, vol. 55, no. 2, pp. 199–207, 2005.

[135] L. Juul, K. J. Pallesen, M. Bjerggaard et al., “Mindfulness-based stress reduction intervention and a waiting list control group in a real-life municipal health care setting,” BMC Public Health, vol. 20, no. 1, p. 409, 2020.

[136] N. Raja-Khan, E. Stener-Victorin, X. Wu, and R. S. Legro, “The physiological basis of complementary and alternative medicines for polycystic ovary syndrome,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 301, no. 1, 2011.